RxDoctor Payments Data

Ashley Goad, APRN

Primary Care · Terryville, CTNPI 1326776162

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Boehringer Ingelheim at 24.5% of the total. Among primary care clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,343in general payments, 2019–2025

Across 110 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$575
  • Lilly USA, LLC$390
  • GSK$299
  • AbbVie$237
  • Takeda Pharmaceuticals U.S.A., Inc.$177
  • Novo Nordisk$144
  • plus $522 from 10 others

What the payments were for

  • Food & beverage$2,343100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,343 in reported general payments places this provider in the 90th percentile of 111 primary care providers in Connecticut.

See all primary care providers in Connecticut

Medicare billing

Part B allowed, 2024
$11,543
Medicare patients
46
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide20$26,974
EliquisApixaban12$10,412
VascepaIcosapent Ethyl13$4,253
Atorvastatin Calcium117$1,063
Diltiazem Hcl11$361
Levothyroxine Sodium21$299
Famotidine18$283
Metoprolol Succinate11$265
Mirtazapine14$247
Lisinopril46$201
Metoprolol Tartrate30$201
Gabapentin17$193
Pantoprazole Sodium14$189
Montelukast Sodium22$177
Tamsulosin Hcl13$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$390$26,97420 claims
PfizerEliquis$128$10,41212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 primary care providers in Connecticut.

Other primary care in Terryville

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →